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Neurobiology
Cyclical and Dose-Dependent Responses of Adult
Human Mature Oligodendrocytes to Fingolimod
Veronique E. Miron,*† Jeffery A. Hall,‡
Timothy E. Kennedy,† Betty Soliven,§
and Jack P. Antel*
From the Neuroimmunology Unit,* the Center for Neuronal
Survival,† and the Division of Neurosurgery,‡ Montreal Neurological
Institute, McGill University, Montreal, Canada; and the Department
of Neurology,§ University of Chicago, Chicago, Illinois
Fingolimod is a sphingosine-1-phosphate (S1P) ana-
logue that has been used in clinical trials as a systemic
immunomodulatory therapy for multiple sclerosis. Fin-
golimod readily accesses the central nervous system,
raising the issue of its direct effects on neural cells. We
assessed the effects of active fingolimod on dissociated
cultures of mature, myelin-producing oligodendrocytes
(OLGs) derived from adult human brain. Human OLGs
express S1P receptor transcripts in relative abundance
of S1P5>S1P3>S1P1, with undetectable levels of S1P4.
Low doses of fingolimod (100 pmol/L to 1 nmol/L) in-
duced initial membrane elaboration (2 days), subse-
quent retraction (4 days), and recurrence of extension
with prolonged treatment (8 days). Higher doses (10
nmol/L to 1 mol/L) caused the opposite modulation of
membrane dynamics. Retraction was rescued by co-
treatment with the S1P3/S1P5 pathway antagonist,
suramin, and was associated with RhoA-mediated cy-
toskeletal signaling. Membrane elaboration was mim-
icked using the S1P1 agonist SEW2871. Fingolimod res-
cued humanOLGs from serum and glucose deprivation-
induced apoptosis, which was reversed with suramin
co-treatment andmimicked using an S1P5 agonist. High
doses of fingolimod induced an initial down-regulation
of S1P5 mRNA levels relative to control (4 hours), sub-
sequent up-regulation (2 days), and recurrent down-
regulation (8 days). S1P1 mRNA levels were inversely
regulated compared with S1P5. These results indicate
that fingolimod modulates maturity- and species-spe-
cific OLG membrane dynamics and survival responses
that are directly relevant for myelin integrity. (Am J
Pathol 2008, 173:1143–1152; DOI: 10.2353/ajpath.2008.080478)
Myelin is a membrane that ensheaths axons to permit
rapid saltatory conduction of action potentials.1 Within
the central nervous system, myelin is produced by oligo-
dendrocytes (OLGs) and continues to undergo a turnover
throughout life.2–4 Myelin and OLGs are the proposed
targets of the immune-mediated injury that underlies the
development of the autoimmune-disease multiple sclero-
sis (MS). OLGs are lost early in the disease process in
specific subtypes of MS; in chronic MS lesions, there is
universal loss of OLGs.5 Fingolimod is being assessed
for MS therapy because of its anti-inflammatory proper-
ties.6 Unlike currently prescribed MS therapies that have
limited access to the central nervous system, orally ad-
ministered fingolimod can penetrate the blood-brain bar-
rier.7 Once it has penetrated the brain parenchyma, fin-
golimod is rapidly phosphorylated by sphingosine kinase
2 (SphK2)-expressing neural cells to its biologically ac-
tive metabolite (fingolimod-phosphate), a lipophilic
sphingosine-1-phosphate (S1P) analogue.8 Although the
active form of the drug demonstrates poor permeability
across the blood-brain barrier, fingolimod is not primarily
phosphorylated in the circulation given the low blood
levels of the sphingosine kinases.8 Autoradiographical
analysis after 1 week of oral treatment with C14-labeled
fingolimod has demonstrated that both the parent drug
and active phosphate metabolite are present at higher
concentrations in the brain relative to the blood, and are
localized to myelin membranes.9 In vitro studies have
demonstrated the capacity of fingolimod-phosphate to
impact known cell survival and cytoskeleton-associated
signaling pathways10–12; together these findings indicate
the potential of fingolimod to influence myelin and OLGs.
Fingolimod-phosphate is an agonist for G-protein-cou-
pled receptors S1P1, -3, -4, and -5, which belong to the
endothelial differentiation gene-related (EDG) family.13,14
EDG receptor mRNA levels are up-regulated at the pe-
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rimeter of MS lesions.15 The immunomodulatory effects of
fingolimod are consequent to its binding to S1P1 on circu-
lating naı¨ve lymphocytes, subsequent endocytosis of the
bound receptor,16,17 down-regulation of S1P1 mRNA lev-
els,18 and resulting blockade of S1P1-dependent efflux
from secondary lymph nodes to target organs.19,20
Rodent-derived mature OLGs express S1P1, S1P3, and
S1P5 isoforms in vitro and in vivo.21,22 Generally, binding to
S1P3 and S1P5 lead to G12/13 activation and membrane
retraction via RhoA GTPase,23,24 whereas S1P1 linkage to
Gi/o is associated with Rac1 and Ras GTPase activation and
subsequent membrane extension and survival.11,17 Previ-
ous studies have demonstrated that Rho GTPase-depen-
dent signaling is crucial in regulating oligodendroglial pro-
cess extension and myelin integrity.25,26 Contrary to
observations with rat pre-OLGs, treatment of mature rat
OLGs with either fingolimod-phosphate or the endog-
enous ligand S1P does not induce cytoskeletal retrac-
tion yet induces a prosurvival response.11,24
Differing receptor affinities and potencies between fin-
golimod-phosphate and S1P suggest the possibility of
inducing distinct responses in target cells.27 We have
previously demonstrated that fingolimod-phosphate can
impact cytoskeletal dynamics and survival responses in
human oligodendrocyte progenitor cells (OPCs),10 which
are the cell type shown to be responsible for myelin repair
in experimental animal systems.28,29 Fingolimod-phos-
phate treatment of human OPCs induced an initial retrac-
tion and subsequent extension of the cytoskeleton, and a
prosurvival response in a death-promoting environ-
ment.10 Our objective was to determine whether fingoli-
mod could impact these same processes in human ma-
ture OLGs, and whether these cells have a distinct
response profile relative to their progenitor counterparts.
For our studies, we used OLGs isolated from the adult
human central nervous system; these are postmitotic
cells that express all markers associated with a mature
myelinating phenotype.30 Unlike their rodent counter-
parts, such cells survive in vitro for prolonged periods
even in the absence of defined growth factors.30 Also in
contrast to these human cells, most rodent-based studies
of mature OLGs, such as those cited above, involve
progenitor cells differentiated in culture. We investigated
the effect of the active phosphorylated form of fingolimod
on dissociated cultures of human adult mature OLGs with
respect to morphology and survival responses implicated
in myelin maintenance, and linked responses with relative
S1P receptor levels and associated signaling pathways.
We used concentrations of fingolimod-phosphate that are
comparable to those used to modulate immune func-
tion31–33 and that have been measured in the brain pa-
renchyma and cerebrospinal fluid of treated animals.9
Materials and Methods
Fingolimod Biological Activity and Lymphocyte
Culture
To demonstrate the biological activity of fingolimod-phos-
phate in vitro, we assessed the effects of the drug on S1P
receptor levels in lymphocytes isolated from healthy hu-
man adults. Previous studies performed with lympho-
cytes derived from fingolimod-treated rodents demon-
strate decreased levels of S1P1 receptor mRNA levels.18
We tested the ability of fingolimod-phosphate to down-
regulate lymphocyte S1P1 mRNA by treating CD8 T cells
with fingolimod-phosphate and performing real-time
quantitative polymerase chain reaction (PCR) for S1P1.
Peripheral blood was drawn and layered over a Ficoll-
Paque (Pharmacia Biotech, Baie d’Urfe, Canada). Cells
were incubated on ice with microbead-conjugated anti-
CD8 antibody (Miltenyi Biotech, Auburn, CA), washed
with MACS buffer (2 mmol/L/L ethylenediaminetetraace-
tic acid, 0.5% fetal calf serum in phosphate-buffered
saline), and separated using positive selection columns
(Miltenyi Biotech) according to the manufacturer’s in-
structions. The CD8 lymphocyte fraction was resus-
pended in serum-free RPMI (Sigma, Oakville, Canada)
with or without 1 mol/L phosphorylated-fingolimod for 15
minutes. RNA was extracted and S1P1 mRNA modulation
was assessed as described below.
Human Adult Mature OLG Culture
Tissue was obtained from surgical resections performed
as treatment for nontumor-related intractable epilepsy in
accordance with the guidelines set by the Biomedical
Ethics Unit of McGill University. Mature OLGs were iso-
lated as previously described.34 After removal of blood
clots, tissue was digested with 0.25% trypsin (Invitrogen,
Burlington, Canada) and 25 g/ml of DNase I (Roche,
Laval, Canada) for 30 minutes at 37°C. Cells were me-
chanically dissociated with a nylon mesh and separated
on a linear 30% Percoll density gradient (Pharmacia Bio-
tech) to remove myelin debris. Two overnight rounds of
differential adhesion in uncoated tissue culture flasks
were used to isolate the floating OLG fraction and reduce
the proportion of contaminating microglia. Cells were plated
in poly-L-lysine-coated glass chamber slides (Nalge Nunc
International, Naperville, IL) in minimal essential medium
with 5% fetal calf serum (Sigma), 1% penicillin-streptomy-
cin, 1% glutamine, 0.1% glucose (all from Invitrogen), at a
density of 105 cells per well. The purity of these cultures has
been previously characterized.35,36
Human Fetal OPC Culture
Human fetal OPC cultures were derived as described10
from central nervous system tissue obtained from 19- to
23-week-old embryos, provided by the Human Fetal Tis-
sue Repository (Albert Einstein College of Medicine,
Bronx, NY). These studies were approved by their and
our institutional review boards. Diced brain tissue was
incubated with 0.25% trypsin (Invitrogen, Grand Island,
NY) and 25 g/ml of DNase I (Roche Diagnostics) at
37°C for 30 minutes and passed through a mesh. A2B5
cells were isolated by immunomagnetic bead separation
using an A2B5 IgM antibody (from a hybridoma), and a
microbead-conjugated rat anti-mouse IgM (Miltenyi Bio-
tech). Cells were resuspended in Dulbecco’s modified
1144 Miron et al
AJP October 2008, Vol. 173, No. 4
Eagle’s medium-F12 supplemented with 1% penicillin-
streptomycin, 1% glutamine (all from Invitrogen), N1 sup-
plement (1; Sigma, St. Louis, MO), thyroid hormone T3
(2 ng/ml, Sigma), basic fibroblast growth factor (20 ng/ml,
Sigma), and platelet-derived growth factor (20 ng/ml,
Sigma), and plated on a confluent bed of lysed and
washed human fetal astrocytes grown on a plastic poly-
L-lysine-coated coverslip (Nunc, Rochester, NY). The pu-
rity of the cultures has been previously characterized.37
Pharmacological Studies
The active phosphorylated form of fingolimod (provided
by Novartis, Basel, Switzerland) was dissolved in di-
methyl sulfoxide/50 mmol/L HCl and diluted in culture
media before each experiment. To identify the receptors
and associated signaling pathways activated by fingoli-
mod-phosphate, cultures were treated with the S1P1-
specific agonist SEW2871 (100 nmol/L; Calbiochem, San
Diego, CA), the S1P5-specific agonist (10 nmol/L, pro-
vided by Novartis), or co-treated with fingolimod-phos-
phate and the S1P3/S1P5 pathway antagonist suramin (1
nmol/L, 100 nmol/L; EMD Bioscience, San Diego, CA).
L--lysophosphatidic acid (LPA) (10 mol/L, Sigma) was
used as a positive control for RhoA GTPase activation.38
Treatments were replaced every 2 days. No effects were
observed when the OLGs were treated with the appro-
priate vehicles used for reconstitution of these products.
Functional Assays
Cytoskeletal Dynamics
To assess process extension of mature OLGs, we deter-
mined the area of myelin-associated glycoprotein (MAG)
staining (1:200, Chemicon, Temecula, CA) or phalloidin-
Alexa 488 staining (1:400, Invitrogen-Molecular Probes) per
cell (m2) using a calibrated optical density image (Scion
Image software NIH, Bethesda, MD) and divided it by the
total number of nuclei in the image. Cell numbers were
quantified with ImageJ software (NIH, Bethesda, MD) using
the watershed tool, to give area of staining per cell (m2/
cell). These cultures had an average of 75 cells per field.
To assess activation of cytoskeletal modulators down-
stream of Rho GTPases in response to pharmacological
agents, we immunostained cells with rabbit polyclonal
anti-sera against phospho-myosin light chain (MLC)-II
(1:50, Thr18/Ser19; Santa Cruz Biotechnology, Santa
Cruz, CA). Phosphorylation levels were determined by
assessing the immunostaining intensity in individual
MAG-positive cells using the histogram function in Adobe
Photoshop (San Jose, CA). Fifteen cells per field in each
20 objective image were quantified; four images per
condition were taken for each of the three independent
samples resulting in 180 cells being quantified for MLC II
phosphorylation levels.
Survival
To induce apoptosis in OLGs, cells were cultured in
media deprived of glucose and serum for 4 days. Only
samples in which the deprivation condition increased the
percentage of apoptotic cells by at least twofold over
basal media levels were used for analysis. Fingolimod-
phosphate, SEW2871, or the S1P5 agonist were diluted in
the deprivation media and applied for the entire 4 days.
Apoptosis was assessed by incubating fixed cells with
the recombinant terminal deoxynucleotidyl transferase kit
(TUNEL; Promega Corp., Madison, WI) with biotin-16-2-
deoxy-uridine-5-triphosphate (Biotin-16-dUTP, Roche)
for 1 hour at 37°C, and incubating with streptavidin-
fluorescein isothiocyante (1:1000; Jackson ImmunoRe-
search, West Grove, PA) for 30 minutes at 37°C. The
percentage of TUNEL and MAG double-immunopositive
cells was determined by manually counting positive cells
in a blinded manner.
Immunocytochemistry
Cells were fixed with 2% paraformaldehyde and blocked
with HHG (1 nmol/L HEPES, 2% heat-inactivated horse
serum, 10% heat-inactivated goat serum, Hanks’ bal-
anced salt solution) for 20 minutes. Primary antibodies
were applied for 1 hour at 4°C. The secondary antibodies
goat anti-mouse Cy3 (1:500, Jackson ImmunoResearch),
and goat anti-rabbit fluorescein isothiocyanate (1:100;
Biosource, Camarillo, CA) were applied for 30 minutes at
4°C. Primary antibody isotype controls showed low non-
specific staining. Cell nuclei were identified using the
Hoechst dye (bis-benzimide, 1:1000; Molecular Probes,
Carlsbad, CA), and slides were mounted with Fluoro-
mount-G (EMS, Hatfield, PA).
RNA-Based S1P Receptor Modulation Studies
After cell lysis with TRIzol (Invitrogen), total RNA was
extracted with the Minielute Qiagen RNeasy mini kit, and
samples were treated with DNase (Qiagen, Mississauga,
Canada). Reverse transcription (RT) was performed on 2
g of RNA, and cDNA was generated using random
hexaprimers (Roche) and the Moloney murine leukemia
virus-RT enzyme (Invitrogen) in a thermocycler at 42°C,
75°C for 60 minutes, 4°C for 10 minutes. For real-time
qPCR, cDNA from CD8 T cells isolated from normal do-
nors and Jurkat T cells were used to create a standard
curve of serial 10-fold dilutions for S1P1, S1P4, S1P5, and
S1P3, respectively,39,40 using primers, TaqMan, and
probes from Assays on Demand by Applied Biosystems
(Melbourne, Australia). Transcript levels were assessed
using the ABI Prism 7000 sequence detection system
(Applied Biosystems) using default temperature settings
(2 minutes at 50°C, 10 minutes at 95°C, followed by 40
cycles of 15 seconds at 95°C, 1 minute at 60°C). Water
controls indicated undetectable levels of noise (data not
shown). -Actin transcript levels were used as endoge-
nous controls for the amount of RNA transcribed, and
primers/probes were designed using the PRIMER ex-
press software (Applied Biosystems).41 All S1P receptor
levels were normalized to the -actin levels in the corre-
sponding sample. Because of poor reactivity/specificity
of commercially available human reactive anti-S1P re-
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ceptor antibodies, we were unable to demonstrate the
specificity of these antibodies on our cells using various
methods, and were thus unable to directly assess expres-
sion and modulation of S1P receptors at the protein level.
Statistical Analyses
Four 20 objective images were captured for each con-
dition for one experiment, and each experiment was re-
peated with at least three different samples. Results are
presented as fold difference greater than control normal-
ized to the mean value in untreated culture conditions at
the respective time point. Comparisons between condi-
tions were made using one-way analysis of variance.
Probability values 0.05 were considered statistically
significant.
Results
Fingolimod Is Functionally Active
Fingolimod-phosphate treatment of CD8 T lymphocytes
for 15 minutes induced a down-regulation of S1P1 mRNA
levels to 0.62  0.006 of control. This is consistent with
the finding that ex vivo T lymphocytes isolated from
fingolimod-treated animals have lower levels of S1P1
transcripts,18 and that in vitro fingolimod-phosphate
treatment induces down-regulation of transfected re-
ceptors.31,42 Our findings support the functional activ-
ity of the fingolimod used in our studies.
Adult Human Mature OLGs Have S1P Receptor
Transcripts
Using real-time quantitative PCR, we characterized the
relative abundance of transcripts for S1P receptors that
can bind fingolimod-phosphate in the OLG cultures un-
der basal culture conditions. We found that human OLGs
express high levels of S1P5, relatively lower levels of
S1P3 and S1P1, and undetectable levels of S1P4 (Figure
1). This is in contrast to the relatively high S1P1 and low
S1P5 transcript levels previously observed in human
OPCs.10
Dose- and Treatment Duration-Dependent
Modulation of Mature OLG Cytoskeleton by
Fingolimod
We observed that fingolimod-phosphate induced cyclic
modulation of mature OLG process dynamics throughout
time in a dose-dependent manner. Untreated cultures
had progressive and maintained membrane elaboration
throughout time (8-day area of MAG staining per cell was
1.84  0.19-fold greater than 2 day cultures). Very low
doses of 1 to 10 pmol/L did not have significant effects on
membrane elaboration (data not shown). Low doses of
fingolimod-phosphate (100 nmol/L) had no significant
effects on process dynamics of mature OLGs at 1 day of
treatment; higher dose treatment (1 mol/L), however,
was associated with a significant process extension (see
Supplemental Figure 1 at http://ajp.amjpathol.org). When
mature OLGs were treated with low doses of fingolimod-
phosphate for 2 days (100 pmol/L, 1 nmol/L), we ob-
served a significant elaboration of membrane (area of
MAG staining was 1.46  0.06-fold and 1.42  0.02-fold
over control, respectively) (Figure 2, A and B). Con-
versely, higher doses (100 nmol/L, 1 mol/L) caused a
reduction in membrane elaboration relative to control
(area of MAG staining was 0.78  0.06-fold and 0.68 
0.05-fold greater than control) (Figure 2, A and B).
By 4 days of fingolimod-phosphate treatment, 100
pmol/L- and 1 nmol/L-treated cultures showed mem-
brane retraction relative to 2-day-treated cultures (area of
MAG staining was 0.67 0.14 and 0.71 0.18 of control,
respectively). In contrast, a recovery in cytoskeletal elab-
oration was observed with 100 nmol/L and 1 mol/L, with
no significant difference in comparison to control (area of
MAG staining was 1.15  0.12-fold and 1.00  0.16 of
control, respectively) (Figure 2, A and B).
By 8 days of treatment, there was a significant recov-
ery of membrane in cultures treated with lower doses
(area of MAG staining was 1.01  0.06-fold greater than
control for 0.1 nmol/L and 0.97  0.04-fold for 1 nmol/L),
and recurrence of retraction in cultures treated with 1
mol/L fingolimod-phosphate (area of MAG staining of
0.42  0.12 of control). Phalloidin staining indicated that
observed responses were associated with an extension
or retraction of filamentous actin-positive processes,
rather than a loss of MAG staining (Figure 2C).
We had previously observed that treatment of human
OPCs with high doses of fingolimod-phosphate (10
nmol/L to 1 mol/L) induced initial cytoskeletal retraction
and subsequent extension. We next sought to determine
whether OPCs also have the potential to respond to fin-
golimod in a dose-dependent manner as observed in
mature OLGs. Unlike the mature OLGs, OPCs responded
to low doses of fingolimod-phosphate (100 pmol/L, 1
nmol/L) in a similar manner than to higher doses (See
Supplemental Figure 2 at http://ajp.amjpathol.org).8 This
suggests that OPCs and mature OLGs can potentially
exhibit cell-type-specific and differing cytoskeletal re-
sponses to fingolimod based on the dose to which they
are exposed.
Figure 1. Human adult mature OLGs have transcripts for sphingosone
1-phosphate (S1P) receptors. qPCR levels for S1P receptors were normalized
to -actin levels in the respective sample and then normalized to control
levels. Human mature OLGs have S1P receptor transcripts in the relative
abundance of S1P5S1P1S1P3, and undetectable S1P4.
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To assess the functional basis behind the fingolimod-
induced modulations in human mature OLG cytoskeletal
dynamics, we treated cultures with S1P receptor- or sig-
naling pathway-specific agonists and antagonists. The
membrane retraction observed with 1 mol/L fingolimod-
phosphate at 2 days was significantly antagonized by
co-treatment with suramin (100 nmol/L) (Figure 2D), an
S1P3/S1P5 pathway antagonist that uncouples these re-
ceptors from their G protein.43,44 Suramin alone had no
significant effect on membrane elaboration. These find-
ings suggest that fingolimod-phosphate induced mem-
brane retraction via S1P3 or S1P5 signaling. The ability of
the S1P1-specific agonist SEW2871 (100 nmol/L) to in-
duce membrane elaboration at 2 days suggests that
S1P1-mediated signaling is sufficient in causing such a
response (Figure 2D).
Functional signaling downstream of S1P receptors was
assessed by evaluating the expected activation of cy-
toskeletal modulators. We associated the observed mem-
brane retraction observed initially with 1 mol/L fingoli-
mod-phosphate with RhoA GTPase-associated myosin
light chain (MLC) II phosphorylation.45 We used another
EDG receptor ligand, LPA, as a positive control because
of its ability to induce RhoA GTPase activation.38,46 A
significant increase in MLC II phosphorylation was ob-
served at 15 minutes of treatment with fingolimod-phos-
phate (1.81  0.05-fold greater than control) or LPA
(1.40  0.05-fold greater than control) (Figure 3, A and
B). At 1 hour of fingolimod-phosphate or LPA treatment,
MLC II phosphorylation decreased relative to 15 minutes
(1.03 0.04-fold and 1.18 0.04-fold of control, respec-
tively) (Figure 3B), demonstrating an expected drop in
activation throughout time.45 The fingolimod-induced in-
crease in phospho-MLC II signal was significantly re-
versed by co-treatment with suramin (Figure 3C), sug-
gesting an S1P3/S1P5-dependent mechanism. Intensity
of phospho-MLC II signal did not change in untreated
cultures throughout time (Figure 3B).
Figure 2. Fingolimod regulates human mature OLG cytoskeleton dynamics in a dose- and treatment duration-dependent manner. A: Representative images of
cultures immunostained against MAG. Untreated cultures showed maintenance of membrane elaboration throughout time (left). Treatment with a low dose of
fingolimod-phosphate (100 pmol/L, middle) induced an initial membrane elaboration (2 days), subsequent retraction (4 days), and recurrent extension (8 days).
Conversely, treatment with a high dose of fingolimod-phosphate (100 nmol/L, right) induced initial membrane retraction (2 days), subsequent elaboration (4
days), and ensuing retraction (8 days). B: Quantification of membrane elaboration expressed as mean area of MAG staining per cell (m2/cell) normalized to
untreated culture values at the respective time point. Treatment with low doses of fingolimod-phosphate (100 pmol/L to 1 nmol/L) induced a cyclic regulation
of membrane elaboration; treatment with higher doses (100 nmol/L to 1 mol/L) provoked a reciprocal modulation of membrane dynamics. *P  0.05 relative
to control; P 0.05 relative to previous time point. C: Quantification of cytoskeletal modulation expressed as mean area of phalloidin staining per cell (m2/cell)
normalized to untreated culture values at the respective time point. *P 0.05, **P 0.01 relative to control; P 0.05, P 0.01, P 0.001 relative to previous
time point. Results confirm those obtained from quantification of area of MAG staining and suggest modifications at the level of the actin cytoskeleton. D:
Co-treatment of cultures with the S1P3/5 pathway antagonist, suramin (100 nmol/L), antagonized the process retraction observed with 1 mol/L fingolimod-
phosphate at 2 days of treatment. Treatment with the S1P1-specific agonist, SEW2871 (100 nmol/L), for 2 days induced significant membrane elaboration relative
to control. *P  0.05 relative to control; P  0.05 relative to fingolimod alone. Scale bar  50 m.
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Fingolimod Promotes Mature OLG Survival
under Apoptotic Conditions
Our previous studies indicated the potential of fingolimod
to promote cell survival signaling in human OPCs under
apoptotic conditions.10 We induced cell death in mature
OLGs by serum and glucose deprivation throughout 4
days to determine whether fingolimod could also support
the survival of these cells. Deprivation conditions in-
creased the percentage of TUNEL-positive mature OLGs
to 6.18  1.7-fold greater than basal media control
(Figure 4A). The low dose of 1 nmol/L was not able to
rescue the cells from apoptosis. However, higher doses
of fingolimod-phosphate (10 nmol/L to 1 mol/L) signifi-
cantly decreased the proportion of apoptotic cells such
that it was not significantly different from basal media
control levels (Figure 4A). Treatment with the S1P1 ago-
nist SEW2871 was not able to rescue OLGs from apopto-
sis (Figure 4A). This contrasts with the finding that
SEW2871 is sufficient in rescuing human OPCs from
apoptosis.10 The fingolimod rescue effect was reversed
when cultures were co-treated with the S1P3/5 pathway
antagonist, suramin, and was mimicked by application of
an S1P5-specific agonist (Figure 4B). This suggests that
fingolimod can promote cell survival signaling in OPCs
and OLGs via different S1P receptors, and also reveals
cell-type-specific dependencies on S1P receptors for
survival signaling.
Fingolimod Modulates S1P Receptor mRNA
Levels
CD8 T lymphocytes were used as positive controls for
S1P1, S1P4, and S1P5 receptor mRNA levels39 and Jur-
kat T cells were used as a control for S1P3 levels.40
Prolonged culture of mature OLGs caused a progressive
decrease in S1P receptor mRNA levels (data not shown),
likely reflecting the impact of S1P in the serum-supple-
mented media on receptor modulation. After fingolimod-
phosphate treatment, we observed a treatment duration-
dependent regulation of S1P1 and S1P5 mRNA levels in
the mature OLG cultures. Exposure to 1 mol/L fingoli-
mod-phosphate caused S1P5 levels to be significantly
down-regulated at 4 hours relative to control; levels were
subsequently up-regulated at 2 days then recurrently
down-regulated at 8 days (Figure 5A). S1P1 mRNA levels
were oppositely modulated at all time points (Figure 5B).
This suggests that these two receptors, which likely regulate
opposing signaling pathways, are cyclically and oppositely
regulated in mature OLGs in response to fingolimod-phos-
phate. In all conditions and at all time points, S1P3 levels
remained low, and undetectable levels of S1P4 persisted.
Discussion
Our in vitro studies reveal that the biologically active form
of fingolimod can exert dose- and treatment duration-
dependent effects on adult human mature OLG morphol-
ogy and survival, with associated modulation of S1P re-
ceptor transcripts. As discussed below, our results with
the human OLGs indicate that there may be substantial
differences compared to rodent cells. These studies sug-
gest that interpretations drawn from rodent in vitro studies
may not be readily extrapolated to human cells and dis-
ease. Furthermore, the direct neurobiological effects of
fingolimod in in vivo animal models, specifically an
animal model of MS, experimental autoimmune en-
cephalomyelitis, are difficult to dissociate from poten-
tial indirect effects mediated via modulation of the
systemic immune cell responses.
Fingolimod Modulates Human OLG Membrane
Elaboration in a Dose- and Treatment Duration-
Dependent Manner
Fingolimod-phosphate induced a cycling of cytoskeletal
responses in human mature OLGs in a dose- and treat-
ment duration-dependent manner. Treatment with lower
doses caused an initial membrane extension, subse-
quent membrane retraction, and recurring extension with
prolonged treatment. Higher doses produced an oppo-
site modulation of responses. Dose-dependent re-
sponses may reflect differing affinities for S1P receptors.
Lower doses of phosphorylated-fingolimod may be more
prone to bind higher affinity S1P1 to induce initial exten-
sion, whereas higher doses may also bind lower affinity
S1P3/S1P5 to trigger retraction. Rat and human OLG
progenitors also show transient cytoskeletal responses on
Figure 3. Fingolimod-induced activation of a cytoskeletal modulator in ma-
ture OLGs indicative of functional signaling downstream of S1P receptors. A:
Representative images of untreated (top) and fingolimod-phosphate-treated
(FTY, 1 mol/L; bottom) mature OLG cultures immunostained for the
nuclear stain Hoechst (left), phospho-myosin light chain (MLC) II (middle),
and MAG, demonstrate that at 15 minutes of treatment fingolimod-phosphate
increases the intensity of phospho-MLC II staining in OLGs relative to control.
B: Quantification of phospho-MLC II staining intensity per cell normalized to
untreated control at the respective time point. fingolimod-phosphate (1
mol/L) and the positive control LPA induce a significant increase in phos-
pho-MLC II staining intensity at 15 minutes, with an expected drop at a later
time point (1 hour). ***P  0.001 relative to control; P  0.001 relative to
previous time point; P  0.01 relative to previous time point. C: The
fingolimod-induced increase in intensity of phospho-MLC II staining per cell
at 15 minutes was negated by co-treatment with the S1P3/5 pathway antag-
onist, suramin (sur, 100 nmol/L), whereas the increase in intensity was still
observed when suramin was applied alone. *P  0.05, **P  0.01 relative to
control; P  0.001 relative to fingolimod-phosphate alone.
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S1P receptor engagement,10,24 although to our knowledge
we are the first to demonstrate a cycling of responses in
mature OLGs. Conversely, neonatal rat OLGs matured in
vitro do not retract membranes on S1P treatment.24 We
documented similar lack of responses with 1 and 2 days of
fingolimod-phosphate treatment of rat matured OLGs (data
not shown), suggesting species-specific differences in re-
sponsiveness to fingolimod. However, disparities between
rodent and human OLG responses may be attributable to
differences in S1P receptor affinities for the ligand,47 recep-
tor levels and coupling to associated signaling pathways,
and sample age/cell maturity.
Membrane retraction in human mature OLGs was as-
sociated with increased phosphorylation of myosin light
chain II, indicative of RhoA GTPase signaling.45 Both the
retraction and the increase in phospho-MLC II signal
were antagonized by co-treatment with the S1P3/S1P5
pathway antagonist, suramin. Our data support that fin-
golimod-phosphate initiates membrane retraction in an
S1P3/S1P5- and RhoA-dependent manner. S1P5-associ-
ated signaling can induce Rho GTPase-dependent mem-
brane retraction in rodent24 and human fetal OPCs.10
S1P1-mediated signaling was sufficient to induce mem-
brane extension in human mature OLGs, similar to previ-
ous observations in human OPCs10 and rodent neu-
rons.23 The importance of Rho GTPase-dependent
modulation of the cytoskeleton in regulating oligodendro-
glial process outgrowth and myelin integrity has been
previously established in vitro and in vivo.25,26
Fingolimod Promotes Human Mature OLG
Survival
We observed that treatment with high doses of fingoli-
mod-phosphate were able to rescue human mature
Figure 4. Fingolimod rescues human adult ma-
ture OLGs from serum and glucose deprivation-
induced cell death. A: Deprivation of culture
supplements for 4 days (black) significantly in-
creased the proportion of apoptotic TUNEL-pos-
itive mature OLGs to 6.2  1.7-fold greater than
basal media levels (gray). A low dose of fingoli-
mod-phosphate (FTY, 1 nmol/L) was unable to
rescue OLGs from apoptosis. Higher doses of
fingolimod-phosphate (10 nmol/L to 1 mol/L)
significantly decreased the percentage of apo-
ptotic cells to control levels. Treatment with the
S1P1-specific agonist, SEW23871 (SEW, 100
nmol/L) was not sufficient in mimicking this
rescue effect. *P  0.05 relative to basal media
condition. B: The prosurvival effect of fingoli-
mod-phosphate was antagonized by co-treat-
ment with the S1P3/5 pathway antagonist,
suramin (100 nmol/L) and was mimicked by a
S1P5-specific agonist (10 nmol/L). ***P  0.001
and *P  0.05 relative to basal media condition.
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OLGs from serum and glucose deprivation-induced cell
death at 4 days of treatment. The S1P1 agonist SEW2871
was not able to promote cell survival in the OLGs, elimi-
nating the possibility that S1P1 signaling is sufficient to
stimulate survival responses in these cells. The fingoli-
mod-induced survival response was antagonized by
suramin co-treatment, and mimicked with the S1P5 ago-
nist, suggesting that fingolimod-phosphate may signal
through S1P5 to rescue human mature OLGs from apo-
ptosis. This suggests that there is a dissociation between
S1P receptor signaling regulating survival and cytoskel-
etal responses in human mature OLGs. Accordingly, S1P
and fingolimod-phosphate treatment of neonatal rat ma-
ture OLGs differentiated in vitro rescues cells from serum
withdrawal-induced apoptosis via S1P5, without any as-
sociated morphological changes.11,24 This study found
that fingolimod-phosphate was not able to rescue rat
pre-OLGs from apoptosis but instead promoted process
retraction via S1P5, suggestive of either a developmental
switch in G-protein or a change in coupling efficiency to
the S1P receptors with oligodendroglial maturation.24 The
ability of fingolimod-phosphate to enhance the survival of
human OPCs in death-inducing environments via S1P1
and not S1P3/510 suggests maturity-dependent re-
sponses to human S1P receptor signaling in the context
of cell survival.
Fingolimod Modulates Relative S1P Receptor
mRNA Levels in Human Adult Mature OLGs
We demonstrated that human mature OLGs have relative
S1P receptor mRNA levels of S1P5S1P3S1P1, and
undetectable levels of S1P4. This is consistent with the
relative mRNA levels of S1P receptor subtypes in neona-
tal rat OLGs.22,48 The comparative levels of S1P receptor
subtypes may influence which ones are preferentially
bound by fingolimod-phosphate and the ensuing cellular
response.
Quantitative real-time PCR revealed that human ma-
ture OLGs reciprocally regulate S1P5 and S1P1 mRNA
levels in a cyclic manner in response to fingolimod-phos-
phate. Treatment with a high dose of fingolimod-phos-
phate induced an initial down-regulation of S1P5, subse-
quent up-regulation, and recurrent down-regulation with
prolonged treatment. Interestingly, S1P1 levels were op-
positely regulated at all time points. Given that fingoli-
mod-phosphate binding to a given S1P receptor subtype
initiates its down-regulation at the mRNA level,18 we in-
terpreted this down-regulation as a readout of which
receptor was bound at a given time.
The initial down-regulation of S1P5 mRNA levels at 4
hours of treatment with 1 mol/L fingolimod-phosphate
would be associated with the observed S1P3/5- and
RhoA-dependent membrane retraction observed with
this dose at 2 days of treatment. The concomitant up-
regulation of S1P1 mRNA levels at 4 hours of treatment
with 1 mol/L fingolimod-phosphate likely increased the
availability of S1P1 receptors to bind fingolimod, thereby
causing S1P1 down-regulation by 2 days of treatment
and a switch in responses to membrane elaboration by 4
days of exposure to fingolimod. The subsequent up-regu-
lation of S1P5 mRNA levels at 2 days of treatment likely
promoted its binding and ensuing down-regulation at 8
days of treatment, which would be associated with the
process retraction observed with this dose at this time point.
These real-time PCR results and the assessment of
receptor-specific associated responses and signaling to-
gether support changes in S1P receptor protein expres-
sion. Our previous findings that human OPCs also dem-
onstrate this cyclic regulation of S1P receptors10
suggests that chronic fingolimod treatment can stimulate
continuous signaling in cells of the human oligodendro-
glial lineage by way of reciprocal cycling of S1P recep-
tors with potentially opposing signaling pathways.
Conclusion
Our studies reveal the capacity of fingolimod to induce
continuous and cyclic functional effects on human OLG
membrane elaboration and survival responses in a dose-
dependent manner. These findings imply that chronic
fingolimod therapy may impact cellular events that are
implicated in the maintenance of myelin. Our observa-
tions are relevant not only in the context of treatment of
MS, but also for other neurological conditions such as
stroke and trauma, in which myelin integrity can be se-
verely compromised.
Figure 5. Fingolimod reciprocally modulates S1P1 and S1P5 receptor tran-
scripts in human adult mature OLGs in a cyclic manner. qPCR results for S1P5
(A) and S1P1 (B) were normalized to -actin in the respective sample and
normalized to untreated cultures at the respective time point. At 4 hours of
treatment with fingolimod-phosphate (1 mol/L), S1P5 is down-regulated
and S1P1 is concomitantly up-regulated relative to control. By 2 days of
treatment, S1P1 is down-regulated and S1P5 is up-regulated. The opposite is
observed at 8 days of treatment. At all time points, S1P3 levels remained low
and S1P4 remained undetectable. S1P receptor levels were progressively
decreased throughout time in untreated cultures likely because of the pres-
ence of S1P in the serum-supplemented media. *P  0.05 relative to control;
P  0.05, P  0.01, P  0.001 relative to previous time point.
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